CMN Weekly (30 September 2022) - Your Weekly CRISPR Medicine News
Some of the best links we picked up around the internet
By: Gorm Palmgren - Sep. 30, 2022
mRNA is frequently modified by N6-methyladenosine (m6A) to regulate biological processes. Now, Chinese researchers have demonstrated a method for CRISPR-dCas13a-based RNA m6A-editing. The method can target RNAs using single or multiple CRISPR RNA (crRNA) arrays to methylate or demethylate m6A in human 293T cells and mouse embryonic stem cells. The method's efficacy was demonstrated by modulation of X chromosome silencing and activation by modulating m6A levels on the non-coding XIST transcript.
A paper in the Journal of Bioethical Inquiry discusses the ethics of using human germline editing for enhancement purposes. The author supports Habermas's argument from human nature that discourages human germline editing and argues that objections to its supposedly genetic essentialist and determinist framework originate from an instrumentalist reading of Habermas's view.